Dose regimen for vancomycin not needing serum peak levels?

Area of Science:

• Neonatal pharmacology
• Pediatric infectious diseases
• Clinical pharmacokinetics

Background:

• Vancomycin is crucial for treating serious Gram-positive infections in neonates.
• Optimizing vancomycin dosing is essential to balance efficacy and toxicity in this vulnerable population.
• Current guidelines often recommend therapeutic drug monitoring, including peak concentrations, for vancomycin.

Purpose of the Study:

• To evaluate the safety and efficacy of a standard vancomycin dosage regimen in neonates.
• To determine the necessity of measuring peak serum vancomycin concentrations in this population.
• To assess achievement of target therapeutic ranges for vancomycin trough and peak levels.

Main Methods:

• Retrospective analysis of 101 infants in a neonatal intensive care unit receiving vancomycin.
• Standardized dosage regimen: 15 mg/kg every 12 or 18 hours based on postnatal age.
• Evaluation of serum vancomycin concentrations against established therapeutic ranges (trough 5-10 mg/L, peak 20-40 mg/L; and trough 5-12 mg/L, peak 15-60 mg/L).

Main Results:

• 46.5% of infants achieved target trough concentrations (5-10 mg/L), with 55.4% reaching 5-12 mg/L.
• 83.2% achieved peak concentrations of 20-40 mg/L, and 99.0% reached 15-60 mg/L.
• 89.4% of infants with trough levels of 5-10 mg/L also had peak levels within 20-40 mg/L.

Conclusions:

• The investigated vancomycin dosage regimen reliably produces acceptable therapeutic serum concentrations in neonates.
• Routine measurement of peak serum vancomycin concentrations is not required when using this specific dosage regimen.
• This finding may streamline vancomycin management in neonatal intensive care units.